We describe a case of Guillain-Barre syndrome (GBS) in a patient with non-Hodgkin's lymphoma (NHL). A 21-year-old woman with a newly diagnosed stage IV high-grade lymphoma (precursor T-cell NHL according to the R.E.A.L. Classification) developed flaccid quadriparesis and bilateral facial diplegia after three weeks of treatment with vincristine, daunorubicin, L-asparaginase and prednisolone. The clinical course and neurological examination were consistent with GBS. Despite treatment with intravenous immunoglobulins her neurological symptoms progressed. Plasmapheresis was therefore initiated followed by intravenous immunoglobulins. After partial remission of neurologic symptoms, induction chemotherapy with cyclophosphamide and cytarabine was continued without any further complication. Three months later, the lymphoma was in complete remission. GBS has been described in Hodgkin's disease and after bone marrow transplantation but is rare in NHL. In patients with NHL who develop neurological symptoms, drug toxicity and nervous system infiltration are the leading cause of neuropathology, but GBS should be considered in the differential diagnosis.
Introduction
Patients with lymphoma frequently develop neurologic abnormalities. The differential diagnosis depends on the clinical setting, but mainly includes nervous system infiltration with lymphoma and drug toxicity, both of which have been well described. Central nervous system infiltration usually can be diagnosed easily by imaging techniques and -in certain circumstances -by subsequent stereotactic biopsy. The occurrence of lymphoma causing peripheral nerve infiltration has been described but is uncommon and difficult to diagnose [1] .
Drug toxicity is the other major cause of neurological abnormalities: High-dose cytarabine may cause cerebellar dysfunction [2] , vinca alcaloids typically induce sensorymotor polyneuropathy [1] while intrathecal chemotherapy with methotrexate and cytarabine may be responsible for myelopathy [3] .
Recently there have been reports on Guillain-Barre syndrome (GBS) diagnosed in patients receiving autologous and allogeneic bone marrow transplantation (BMT) for hematologic malignancies [4, 5] and breast cancer [6] . GBS has previously been described in association with lymphomas, especially with Hodgkin's disease [1] . GBS is an inflammatory demyelinating symmetrical polyneuropathy involving peripheral and cranial nerves and roots. It is characterized by areflexia and an ascending, predominantly motor neuropathy that may affect cranial nerves. The pathogenesis of GBS is unclear, but there is strong evidence for an immune-mediated process [7] .
In chemotherapy-treated patients the differential diagnosis of neurological abnormalities is heavily influenced by the drugs being administered and therefore signs and symptoms indicating an alternative diagnosis may be misinterpreted. We report the occurrence of GBS in a patient with high-grade non-Hodgkin's lymphoma (NHL) who was being treated with a vincristine containing induction chemotherapy.
Case report
In October 1997, a 21-year-old woman was admitted with suspected malignant lymphoma. Clinical staging by imaging techniques showed large mediastinal masses with lung involvement and enlarged thoracic and abdominal lymph nodes. Extensive pericardia! and pleural effusions as well as ascites were present. Immunofluorescence analysis of pleural effusion revealed a predominance of T cells (positive for CD3, CD5, CD7, CD10 and CD45). Lymph node histopathology showed a precursor T-NHL (according to the R.E.A.L. Classification).
Immunohistochemistry was positive for T-cell markers (CD3 and CD45R0) but negative for monotypic immunoglobulin expression. Bone marrow aspirate and biopsy showed less than 5% blasts. White blood count was 13.9 x 1O 9 /1 without atypical lymphocytes, hemoglobin 11.6 g/dl, thrombocytes 492 x 1O 9 /1 and LDH 442 U/l. According to the Ann-Arbor classification, she had stage IVB disease.
Because of the large tumor masses, therapy with vincristine (2 mg, day 1) and dexamethasone (20 mg, On day 16 (all further dates are indicated relative to the start of full induction chemotherapy), our patient complained of weakness of the lower extremities. This progressed until day 19 when it was involving the arms with marked paresis of the proximal muscles. In addition, the patient reported mild paresthesia and hypesthesia in the tips of her fingers and toes. Difficulty in swallowing was reported, although endoscopic examination of pharyngeal motility was normal.
A neurologic examination revealed no cognitive deficits and cerebellar function was normal. Cranial nerve examination showed moderate bilateral facial diplegia. Motor examination revealed a symmetrical flaccid quadriparesis (strength: 2/5 to 3/5). Sensory examination demonstrated mild decrease of vibrationsense in both feet as well as reduced sensation in all fingers and toes bilaterally. Reflexes were absent in both her arms and legs.
On day 19, a CSF specimen yielded 5/3 cells without evidence of malignant cells. Glucose was 0,56 g/1, lactate 0.21 g/1 and protein was 0.53 g/1. No CSF oligoclonal bands were detected. Intrathecal antibodies to Varizella zoster virus, Herpes simplex virus, cytomegalovirus and Epstein-Barr virus (VCA) were negative.
Nerve conduction studies revealed moderate prolongation of distal motor latency, but marked reduction in motor conduction velocity and motor amplitude. F-waves were absent in the medianus study. Electromyography of the right anterior tibialis muscle, the right vastus lateralis muscle and the right interosseus (I) muscle showed no signs of denervation. Bedside vital capacity measurement was subnormal but of limited significance due to her facial diplegia. On the basis of the clinical course and neurologic tests, a diagnosis of GBS was made.
Treatment was started on day 20 and consisted in intravenous human immunoglobulins (30 g Sandoglobulin®, Novartis Pharma GmbH) for five consecutive days starting on day 20 of chemotherapy. The quadriparesis did not stabilize and motor function in her extremities decreased (strength: 1/5 to 2/5). Bronchial mucous retention required repeated bronchoscopic suction due to involvement of respiratory muscles but respiratory failure did not occur. Standard plasmapheresis (50 ml/kg) was instituted on days 30-33 followed by another course of intravenous human immunoglobulins (30 g Sandoglobulin®) for five consecutive days.
Progress of the paresis was halted, and the marked improvement of her respiratory function permitted further chemotherapy on day 39, consisting of cyclophosphymide (1000 mg/m 2 , days 1, 15 and 29), cytarabine (75 mg/m 2 , days 3-6, 10-3, 17-20, 24-27) and mercaptopurine (60 mg/m 2 , days 1-29). The clinical findings, chemotherapy for NHL and treatment of her GBS are summarized in Figure 1 .
Chemotherapy did not result in any deterioration of neurologic symptoms. The patient was discharged after three months but continued to receive intensive physical therapy in a rehabilitation facility. Computed tomography of the chest showed complete response of the lymphoma and a bone marrow biopsy was negative. Prophylactic radiation of the brain (24 Gy) was performed as outpatient. To avoid the scheduled high-dose cytarabine chemotherapy to be given simultaneously, maintenance chemotherapy with methotrexate (20 mg/m 2 weekly) and mercaptopurine (60 mg/m 2 daily) was started. Combination chemotherapy was continued six weeks after completion of radiation including sequential high-dose cytarabine, mitoxantrone, high-dose methotrexate and asparaginase followed by reinduction chemotherapy as proposed in the German multicenter T-ALL protocol. No further intrathecal chemotherapy was given.
Discussion
It is not unusual to see neurological symptoms in patients undergoing treatment for malignant lymphoma. When our patient reported weakness and paresthesia in her legs on day 16, the first hypothesis was that this was a sensory polyneuropathy caused by chemotherapy. The patient had received four doses of vincristine within the preceding two weeks, and polyneuropathy is a common side effect of this drug. The most common differential diagnosis at that time would have been neurological involvement from her lymphoma, however this was unlikely because the neurological signs progressed while the lymphoma was shrinking at other sites. Although clinical signs of vincristine polyneuropathy may vary, proximal muscular weakness does not belong to them and led to the search for other causes. At first glance however, this sign may be mistaken as gait impediment due to severe distal hypo-and paresthesia in patients with polyneuropathy. In this case it became evident that the sensory signs were much milder than the motor deficit, and were limited to fingers and toes.
Rapid progression of the proximal symmetrical motor weakness over days [16] [17] [18] [19] , together with areflexia, led to the first suspicion of GBS of which these are the two cardinal symptoms (see Table 1 ). Our patient also showed most of the features, which strongly support the diagnosis of GBS, including progression of symptoms over days to four weeks, relative symmetry of symptoms, mild sensory symptoms or signs, bilateral weakness of facial muscles and absence of fever at the onset. Once the suspicion was raised, mild symptoms of cranial nerve involvement, i.e., a discrete swallowing disorder, were not overlooked. Viral infections are typically associated to the onset of GBS but no clinical signs for any infection were found at this time or later.
The next diagnostic procedure used to differentiate between different peripheral nerve diseases was electrophysiological testing. This demonstrated characteristic findings of demyelination. Electrophysiological criteria established by Asbury and Cornblath [8] are given in Table 2 . Toxic polyneuropathy could be excluded: Neither clinical course with proximally accentuated flaccid quadriparesis and bilateral cranial nerve involvement nor electrophysiological examination without evidence of denervation but reduced conduction velocities indicating a conduction block were consistent with a vincristine induced polyneuropathy. Therefore we did not perform a sural biopsy. Table 2 . Electrodiagnostic criteria for demyelation of peripheral nerve. For diagnosis of GBS. three out of four features must be fulfilled (adapted from Asbury and Cornblath [8] ).
• Reduction in conduction velocity in two or more motor nerves • Conduction block or abnormal temporal dispersion in one or more motor nerves • Prolonged distal latencies in two or more nerves • Absent F-waves or prolonged minimum F wave latencies in two or more motor nerves
Several cases on GBS in the setting of autologous and allogeneic bone marrow transplantation (BMT) for breast cancer [4, 5] and hematologic malignancies [6] have been reported. In a recent review, Wen et al. reported on GBS following allogeneic bone marrow transplantation [4] . Three mechanisms by which GBS could be related to BMT were discussed: First, higher rate of infections in the post-transplant period could induce aberrant immunologic response to the infection, resulting in GBS. Second, GBS could be regarded as a manifestation of graft-ver?i«-host disease (GVHD) and third, GBS might be due to drug toxicity. In summary, GBS seems to be less common after autologous than allogeneic BMT and occurs earlier in the immediate post-transplant period.
Johnson et al. [2] describe a case of GBS temporally related to administration of high-dose systemic cytarabine and total body irradiation used as a conditioning regimen for allogeneic BMT. Cerebellar dysfunction, which would be typical for cytarabine toxicity, was followed by almost complete paralysis and reversible respiratory failure. Sural biopsy yielded inconclusive results. The authors attribute the GBS-like symptoms to a cytarabine induced neuropathy.
Boiron et al. [9] reported an isolated peripheral nerve relapse in a patient with acute lymphoblastic leukemia masquerading as GBS. Although clinical and electrophysiological features were consistent with GBS, peripheral nerve biopsy revealed leukemic infiltration. Toren et al. [10] have described a patient with primary central nervous system lymphoma of the Burkitt type whose initial presentation resembled GBS. Lumbar puncture disclosed a marked pleocytosis, including lymphoblasts. In summary, various diseases can clinically present as GBS masquerading an underlying pathology.
Effects of lymphoma on the peripheral nervous system have been reviewed by Vallat et al. [11] and Hughes et al. [1] . There have been at least 10 reports of GBS in association with Hodgkin's disease, but association with non-Hodgkin's-lymphoma is rare. Chronic inflammatory demyelinating polyneuropathy (CIDP) in lymphoproliferative disease has been distinguished from GBS by its subacute or chronic course but both might be regarded as a part of a spectrum. Paraneoplastic neuropathy is another rare complication of lymphomas and small-cell lung carcinoma including peripheral neuropathy as well as cerebellar degeneration. Unfortunately, in most cases therapy of the underlying lymphoma does not result in improvement of paraneoplastic symptoms References Plasma exchange (PE) has been regarded as standard therapy for GBS leading to faster improvement and shorter periods of artificial ventilation when compared to supportive care alone [12, 13] . Best results are obtained when PE is started in the first week after onset of symptoms.
Two large multicenter, randomised trials [14, 15] , including 150 and 383 adults respectively, addressed the relative efficacy of PE (50 ml/kg daily for five days) and intravenous immunoglobulin (IVIg) (0.4 g/kg daily for five days) for the treatment of severe acute GBS within two weeks from the onset of neuropathic symptoms. In both studies, the clinical endpoint was defined as improvement at four weeks by a least one grade on a sevenpoint scale of motor function. In the trial conducted by van der Meche et al. [14] , IVIg have been reported being at least equally effective as PE but the trial was smaller than the PE trials performed in the past [12, 13] . The plasma exchange/Sandoglobuoin Guillain-Barre syndrome trial group [15] has undertaken a similar study with an identical predefined outcome measure to find out whether IVIg is equivalent or superior to PE and whether PE followed by IVIg is superior to the better single treatment. The authors concluded that PE and IVIg had equivalent efficacy. Combination therapy with PE followed by IVIg did not confer a sigificant advantage in the treatment of severe GBS.
As discussed, patients receiving IVIg or PE improve faster than those with supportive care alone. Vedeler et al. [16] reexamined 52 patients 1-14 years (median 7 years) after the initial onset of symptoms, 20 (39%) of whom were treated with plasma exchange. Three of these patients received PE after two weeks of onset of symptoms. At the follow-up 38 patients (73%) reported being completely symptom-free. The authors conclude that although previously beneficial effects of PE could be shown at short-term endpoints up to six months, PE had no significant influence on long-term disability.
In summary we describe the rare association of NHL and GBS in a young woman treated with a vincristine containing chemotherapy. Toxic polyneuropathy was ruled out. Therapy with IVIg did not result in clinical improvement, and treatment therefore was repeated including PE. To date the patient is alive and in complete remission of her lymphoma, though she has residual paresis affecting extension of her hands and feet. Although rare, GBS should be considered in the differential diagnosis of neurologic symptoms in chemotherapy-treated lymphoma patients.
